Document is current
Any future updates will be listed below
-
Authors
Jenkins, Zoe M. https://orcid.org/0000-0002-8551-0792
Chait, Lior M.
Cistullo, Leonardo
Castle, David J.
- License Information
-
More Information
Article History
Received: 21 May 2020
Accepted: 7 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: The study was granted ethics approval from the Human Research Ethics Committee at St Vincent’s Hospital, Melbourne and all procedures were in line with the Declaration of Helsinki. Informed consent was obtained from all participants.
: Not applicable.
: DJC has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag,Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, Seqirus; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova. He is founder of the Optimal Health Program, currently operating as Optimal Wellness. He is on the boards of both Mind Medicine Australia and The Mental health Foundation of Australia. He does not knowingly have stocks or shares in any pharmaceutical company. No other authors report any conflicts of interest.
